Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model

International Journal of Antimicrobial Agents

Volumn 33, Issue 1, 2009, Pages 33-39

  Song, Joon Young ^a   Cheong, Hee Jin ^a   Lee, Jacob ^a   Sung, Ah Kyeong ^a   Kim, Woo Joo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Acinetobacter baumannii; Colistin; In vivo; Pneumonia; Rifampicin

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; COLISTIMETHATE; IMIPENEM; RIFAMPICIN; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIOSTASIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HOSPITAL INFECTION; IN VIVO STUDY; INOCULATION; LOW DRUG DOSE; LUNG BIOPSY; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLASMA CLEARANCE; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; IMMUNOSUPPRESSION; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PNEUMONIA, BACTERIAL; RIFAMPIN; TREATMENT OUTCOME;

EID: 59349103552     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.07.008     Document Type: Article

References (27)

1. Lortholary O., Fagon J.Y., and Hoi A.B. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 20 (1995) 790-796
2. Cisneros J.M., Reyes M.J., and Pachon J. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22 (1996) 1026-1032
3. Saballs M., Pujol M., and Tubau F. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58 (2006) 697-700
4. Wolff M., Joly-Guillou M.L., Farinotti R., and Carbon C. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 43 (1999) 1406-1411
5. Pachón-Ibáñez M.E., Fernández-Cuenca F., Docobo-Pérez F., Pachón J., and Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 58 (2006) 689-692
6. Song J.Y., Kee S.Y., and Hwang I.S. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60 (2007) 317-322
7. Hu W.S., Yao S.M., Fung C.P., Hsieh Y.P., Liu C.P., and Lin J.F. An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007) 3844-3852
8. Loehfelm T.W., and Campagnari A.A. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol 190 (2008) 1036-1044
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard. Document M7-A7. Wayne PA: CLSI; 2006.
10. Hogg G.M., Barr J.G., and Webb C.H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 41 (1998) 494-495
11. Montero A., Ariza J., and Corbella X. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 46 (2002) 1946-1952
12. Lefort A., Lafaurie M., and Massias L. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 47 (2003) 216-222
13. Nannini E.C., Pai S.R., Singh K.V., and Murray B.E. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 47 (2003) 529-532
14. Yin L.Y., Lazzarini L., Li F., Stevens C.M., and Calhoun J.H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55 (2005) 995-1002
15. Lorian V. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 4th ed. (1996), Williams and Wilkins, Philadelphia, PA pp. 339-341
16. Li J., Rayner C.R., and Nation R.L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006) 2946-2950
17. Owen R.J., Li J., Nation R.L., and Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59 (2007) 473-477
18. Taccone F.S., Rodriguez-Villalobos H., and De Backer D. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25 (2006) 257-260
19. Motaouakkil S., Charra B., and Hachimi A. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53 (2006) 274-278
20. Peleg A.Y., Adams J., and Paterson D.L. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007) 2065-2069
21. Li J., Nation R.L., Owen R.J., Wong S., Spelman D., and Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45 (2007) 594-598
22. Montero A., Ariza J., and Corbella X. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54 (2004) 1085-1091
23. Lee H.W., Koh Y.M., and Kim J. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect 14 (2008) 49-54
24. Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z., Jones R.A., and Miller S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436 (2005) 1171-1175
25. Landry R.M., An D., Hupp J.T., Singh P.K., and Parsek M.R. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol Microbiol 59 (2006) 142-151
26. Schaber J.A., Triffo W.J., and Suh S.J. Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect Immun 75 (2007) 3715-3721
27. Pachón-Ibáñez M.E., Jiménez-Mejías M.E., Pichardo C., Llanos A.C., and Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 48 (2004) 4479-4481